Analysts peg Genentech bid at $107.50

How much might be enough for Genentech? Analysts expect Roche to hike its bid to $107.50 a share, on average, up from its first, rejected offer of $89 per share. At that price, the deal would be worth $53 billion. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.